{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:22:28Z","timestamp":1790979748932,"version":"4.1.0"},"reference-count":158,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1617,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1111\/j.1365-2036.2011.04637.x","type":"journal-article","created":{"date-parts":[[2011,3,29]],"date-time":"2011-03-29T07:32:23Z","timestamp":1301383943000},"page":"1071-1086","source":"Crossref","is-referenced-by-count":53,"title":["Review article: the treatment of functional abdominal bloating and distension"],"prefix":"10.1111","volume":"33","author":[{"given":"M.","family":"Schmulson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,3,29]]},"reference":[{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/0016-5085(92)90320-X","article-title":"Symptoms of irritable bowel syndrome in a British urban community: consulters and nonconsulters","volume":"102","author":"Heaton","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1023\/A:1005554103531","article-title":"Abdominal pain, bloating, and diarrhea in the United States: prevalence and impact","volume":"45","author":"Sandler","year":"2000","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/gut.42.5.690","article-title":"Identification of distinct upper and lower gastrointestinal symptom groupings in an urban population","volume":"42","author":"Talley","year":"1998","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1046\/j.1365-2036.2002.01369.x","article-title":"Review article: bloating in functional bowel disorders","volume":"16","author":"Zar","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1053\/j.gastro.2005.06.062","article-title":"Abdominal bloating","volume":"129","author":"Azpiroz","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1136\/gut.2007.142810","article-title":"Prevalence and risk factors for abdominal bloating and visible distention: a population-based study","volume":"57","author":"Jiang","year":"2008","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1111\/j.1572-0241.2001.05336.x","article-title":"Sensation of bloating and visible abdominal distension in patients with irritable bowel syndrome","volume":"96","author":"Chang","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/j.1572-0241.2007.01755.x","article-title":"Abdominal bloating in employed adults: prevalence, risk factors, and association with other bowel disorders","volume":"103","author":"Tuteja","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB9|cit9","first-page":"115","volume-title":"The Functional Gastrointestinal Disorders","author":"Thompson","year":"1994"},{"issue":"Suppl. 2","key":"10.1111\/j.1365-2036.2011.04637.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"II43","DOI":"10.1136\/gut.45.2008.ii43","article-title":"Functional bowel disorders and functional abdominal pain","volume":"45","author":"Thompson","year":"1999","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB11|cit11","first-page":"487","volume-title":"Rome III: The Functional Gastrointestinal Disorders","author":"Longstreth","year":"2006"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/BF01303162","article-title":"US householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact","volume":"38","author":"Drossman","year":"1993","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11938-005-0024-x","article-title":"Bloating and intestinal gas","volume":"8","author":"Jones","year":"2005","journal-title":"Curr Treat Options Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"G138","DOI":"10.1152\/ajpgi.2001.281.1.G138","article-title":"Mechanisms of intestinal gas retention in humans: impaired propulsion versus obstructed evacuation","volume":"281","author":"Serra","year":"2001","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/gut.48.1.14","article-title":"Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome","volume":"48","author":"Serra","year":"2001","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/ajg.2010.75","article-title":"Colonic responses to gas loads in subgroups of patients with abdominal bloating","volume":"10","author":"Hernando-Harder","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/070674379303800703","article-title":"Anxiety and depression in patients with abdominal bloating","volume":"38","author":"Song","year":"1993","journal-title":"Can J Psychiatry"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00004836-199407000-00007","article-title":"Functional abdominal bloating","volume":"19","author":"Sullivan","year":"1994","journal-title":"J Clin Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB19|cit19","first-page":"375","article-title":"Intestinal gas production from bacterial fermentation of undigested carbohydrate in irritable bowel syndrome","volume":"84","author":"Haderstorfer","year":"1989","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1136\/gut.32.6.662","article-title":"Abdominal distension in female patients with irritable bowel syndrome: exploration of possible mechanisms","volume":"32","author":"Maxton","year":"1991","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1053\/j.gastro.2009.01.067","article-title":"Abdominal distention results from caudo-ventral redistribution of contents","volume":"136","author":"Accarino","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1365-2982.2005.00666.x","article-title":"Towards a better understanding of abdominal bloating and distension in functional gastrointestinal disorders","volume":"17","author":"Houghton","year":"2005","journal-title":"Neurogastroenterol Motil"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1001\/jama.292.7.852","article-title":"Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome","volume":"292","author":"Lin","year":"2004","journal-title":"JAMA"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB24|cit24","first-page":"392","article-title":"Octylonium bromide in the treatment of the irritable bowel syndrome: a clinical-functional study","volume":"39","author":"Baldi","year":"1992","journal-title":"Hepatogastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1572-0241.2002.05692.x","article-title":"Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms","volume":"97","author":"Fidelholtz","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000185719","article-title":"Evaluation of Crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients","volume":"78","author":"Mangel","year":"2008","journal-title":"Digestion"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB27|cit27","first-page":"317","article-title":"Levosulpiride in functional dyspepsia: a multicentric, double-blind, controlled trial","volume":"28","author":"Corazza","year":"1996","journal-title":"Ital J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/0016-5085(79)90012-X","article-title":"Prifinium bromide in the treatment of the irritable colon syndrome","volume":"77","author":"Piai","year":"1979","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/j.1365-2036.2010.04265.x","article-title":"Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation - a double-blind, randomized, placebo-controlled, study","volume":"31","author":"Lembo","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1053\/j.gastro.2009.12.050","article-title":"Efficacy of linaclotide for patients with chronic constipation","volume":"138","author":"Lembo","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1136\/gut.2005.077503","article-title":"Acontrolled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome","volume":"55","author":"Tack","year":"2006","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2036.2008.03881.x","article-title":"Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies","volume":"29","author":"Drossman","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.cgh.2008.02.058","article-title":"Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence","volume":"6","author":"Shepherd","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl. 1","key":"10.1111\/j.1365-2036.2011.04637.x-BIB34|cit34","first-page":"S223","article-title":"Otilonium bromide improves and delays time to post-treatment relapse in irritable bowel syndrome","volume":"138","author":"Tack","year":"2010","journal-title":"Gastroenterology"},{"issue":"Suppl. 1","key":"10.1111\/j.1365-2036.2011.04637.x-BIB35|cit35","first-page":"S53","article-title":"Efficacy and safety of once daily linaclotide administered orally for 12\u2003weeks in patients with chronic constipation: results from 2 randomized, double blind, placebo-controlled phase 3 trials","volume":"138","author":"Lembo","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation","volume":"364","author":"Pimentel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.cgh.2005.12.023","article-title":"Disaccharide digestion: clinical and molecular aspects","volume":"4","author":"Robayo-Torres","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/j.1552-4604.1974.tb01382.x","article-title":"A double-blind trial of simethicone in functional disease of the upper gastrointestinal tract","volume":"14","author":"Bernstein","year":"1974","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.gcb.2008.09.021","article-title":"Efficacy of an activated charcoal-simethicone combination in dyspeptic syndrome: results of a randomized prospective study in general practice","volume":"33","author":"Lecuyer","year":"2009","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"A2313","DOI":"10.1136\/bmj.a2313","article-title":"Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis","volume":"337","author":"Ford","year":"2008","journal-title":"BMJ"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB42|cit42","unstructured":"Quigley E Fried M Gwee KA et\u00a0al. Irritable Bowel Syndrome: A Global Perspective. World Gastroenterology Organization Global Guidelines http:\/\/www.worldgastroenterology.org\/irritable-bowel-syndrome.html"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/030006059702500501","article-title":"Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results","volume":"25","author":"Delvaux","year":"1997","journal-title":"J Int Med Res"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1185\/03007998009109464","article-title":"A three-part controlled study of trimebutine in the treatment of irritable colon syndrome","volume":"6","author":"L\u00fcttecke","year":"1980","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3748\/wjg.v16.i5.547","article-title":"A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome","volume":"16","author":"Darvish-Damavandi","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB46|cit46","first-page":"273","article-title":"The effect of trimebutine on the psychosocial adjustment to illness in the irritable bowel syndrome","volume":"44","author":"Dumitra\u015fcu","year":"2006","journal-title":"Rom J Intern Med"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB47|cit47","first-page":"305","article-title":"Octylonium bromide: a smooth muscle relaxant which interferes with calcium ions mobilization","volume":"264","author":"Maggi","year":"1983","journal-title":"Arch Int Pharmacodyn Ther"},{"issue":"Suppl. 1","key":"10.1111\/j.1365-2036.2011.04637.x-BIB48|cit48","first-page":"60","article-title":"Clinical and functional evaluation of the efficacy of otilonium bromide: a multicenter study in Italy","volume":"23","author":"Baldi","year":"1991","journal-title":"Ital J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1046\/j.1365-2036.1998.00397.x","article-title":"Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study","volume":"12","author":"Battaglia","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1097\/00042737-200212000-00008","article-title":"Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome","volume":"14","author":"Glende","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"Suppl. 1","key":"10.1111\/j.1365-2036.2011.04637.x-BIB51|cit51","first-page":"67","article-title":"Aleatory clinical study comparing otilonium bromide with a fiber-rich diet in the treatment of irritable bowel syndrome","volume":"23","author":"Villagrasa","year":"1991","journal-title":"Ital J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/BF02936952","article-title":"Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial","volume":"32","author":"Liu","year":"1997","journal-title":"J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.dld.2007.02.006","article-title":"Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: aprospective double blind placebo-controlled randomized trial","volume":"39","author":"Cappello","year":"2007","journal-title":"Dig Liver Dis"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1136\/gut.28.11.1510","article-title":"Double blind study of ispaghula in irritable bowel syndrome","volume":"28","author":"Prior","year":"1987","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2036.1993.tb00074.x","article-title":"Calcium polycarbophil compared with placebo in irritable bowel syndrome","volume":"7","author":"Toskes","year":"1993","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1572-0241.2000.01765.x","article-title":"A randomized, placebo-controlled, multicenter study of the safety and efficacy of a new polyethylene glycol laxative","volume":"95","author":"DiPalma","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1097\/SMJ.0b013e318157ec8f","article-title":"A comparison of polyethylene glycol laxative and placebo for relief of constipation from constipating medications","volume":"100","author":"DiPalma","year":"2007","journal-title":"South Med J"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"C1173","DOI":"10.1152\/ajpcell.00528.2003","article-title":"SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents","volume":"287","author":"Cuppoletti","year":"2004","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"G942","DOI":"10.1152\/ajpgi.00264.2005","article-title":"Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers","volume":"290","author":"Camilleri","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"G295","DOI":"10.1152\/ajpgi.90558.2008","article-title":"Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects","volume":"296","author":"Sweetser","year":"2009","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB61|cit61","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1572-0241.2007.01524.x","article-title":"Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation","volume":"1031","author":"Johanson","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1053\/j.gastro.2007.06.067","article-title":"Effect of 5\u2003days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome","volume":"133","author":"Andresen","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/j.1365-2982.2009.01425.x","article-title":"Translating 5-HT receptor pharmacology","volume":"21","author":"Sanger","year":"2009","journal-title":"Neurogastroenterol Motil"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-2036.2004.01867.x","article-title":"Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics","volume":"19","author":"Tonini","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB65|cit65","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/bmj.2.5752.25","article-title":"Controlled trial of metoclopramide in the treatment of flatulent dyspepsia","volume":"2","author":"Johnson","year":"1971","journal-title":"Br Med J"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB66|cit66","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1542-3565(04)00059-X","article-title":"Levosulpiride and cisapride in the treatment of dysmotility-like functional dyspepsia: a randomized, double-masked trial","volume":"2","author":"Mearin","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB67|cit67","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1185\/03007998009109491","article-title":"Use of the peripheral dopamine antagonist, domperidone, in the management of gastro-intestinal symptoms in patients with irritable bowel syndrome","volume":"6","author":"Milo","year":"1980","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB68|cit68","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1136\/gut.24.12.1135","article-title":"Oral domperidone: double blind comparison with placebo in irritable bowel syndrome","volume":"24","author":"Cann","year":"1983","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB69|cit69","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejphar.2004.10.003","article-title":"Characterization of functional effects of Z-338, a novel gastroprokinetic agent, on the muscarinic M1, M2, and M3 receptors expressed in Xenopus oocytes","volume":"505","author":"Doi","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB70|cit70","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1365-2982.2009.01261.x","article-title":"A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia","volume":"21","author":"Tack","year":"2009","journal-title":"Neurogastroenterol Motil"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB71|cit71","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1155\/1997\/314839","article-title":"A double-blind randomized study of cisapride in the treatment of nonulcer dyspepsia. The Canadian Cisapride Nud Study Group","volume":"11","author":"Champion","year":"1997","journal-title":"Can J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB72|cit72","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2036.1995.tb00364.x","article-title":"Efficacy of cisapride therapy in functional dyspepsia","volume":"9","author":"Kellow","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB73|cit73","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3109\/00365529309098323","article-title":"Cisapride in chronic dyspepsia: results of a double-blind, placebo-controlled trial","volume":"195","author":"Chung","year":"1993","journal-title":"Scand J Gastroenterol Suppl"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB74|cit74","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3109\/00365529509089785","article-title":"A double-blind, randomized, placebo-controlled trial of cisapride in Saudi Arabs with functional dyspepsia","volume":"30","author":"Al-Quorain","year":"1995","journal-title":"Scand J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB75|cit75","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1046\/j.1365-2036.2000.00801.x","article-title":"Cisapride provides symptomatic relief in functional dyspepsia associated with gastric myoelectrical abnormality","volume":"14","author":"Chen","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB76|cit76","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/00365529850166833","article-title":"The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation","volume":"33","author":"Farup","year":"1998","journal-title":"Scand J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB235|cit77","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1046\/j.1365-2036.1997.133311000.x","article-title":"Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome","volume":"11","author":"Sch\u00fctze","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB78|cit78","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004836-199102000-00012","article-title":"\u201cProkinetic\u201d treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride","volume":"13","author":"Van Outryve","year":"1991","journal-title":"J Clin Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB79|cit79","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0016-5085(00)70251-4","article-title":"Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome","volume":"118","author":"Prather","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB80|cit80","first-page":"1906","article-title":"Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials","volume":"103","author":"Vakil","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB81|cit81","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1046\/j.1365-2036.2001.01094.x","article-title":"Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation","volume":"15","author":"M\u00fcller-Lissner","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB82|cit82","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1046\/j.1365-2036.2002.01372.x","article-title":"A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation","volume":"16","author":"Novick","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB83|cit83","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/gut.52.5.671","article-title":"An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome","volume":"52","author":"Kellow","year":"2003","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB84|cit84","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1136\/gut.2005.070789","article-title":"A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation","volume":"54","author":"Tack","year":"2005","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB85|cit85","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1542-3565(04)00356-8","article-title":"Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial","volume":"2","author":"Johanson","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB86|cit86","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/j.1572-0241.2005.40749.x","article-title":"Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study","volume":"100","author":"Kamm","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB87|cit87","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2036.2006.03230.x","article-title":"Efficacy of tegaserod for functional constipation in Chinese subjects: a randomized double-blind controlled trial in a single centre","volume":"25","author":"On Chan","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB88|cit88","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/j.1572-0241.2008.01815.x","article-title":"The FDA\u2019s decision-making process: isn\u2019t it time to temper the principle of protective paternalism?","volume":"103","author":"Brandt","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB89|cit89","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.2146\/news070044","article-title":"Novartis suspends tegaserod sales at FDA\u2019s request","volume":"64","author":"Thompson","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB90|cit90","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/gut.2003.035279","article-title":"Influence of erythromycin on gastric emptying and meal related symptoms in functional dyspepsia with delayed gastric emptying","volume":"54","author":"Arts","year":"2005","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB91|cit91","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1023\/A:1018883731556","article-title":"Colchicine is an effective treatment for patients with chronic constipation: an open-label trial","volume":"42","author":"Verne","year":"1997","journal-title":"Dig Dis Sci"},{"issue":"Suppl. 1","key":"10.1111\/j.1365-2036.2011.04637.x-BIB92|cit92","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2982.2006.00876.x","article-title":"Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity","volume":"19","author":"Bueno","year":"2007","journal-title":"Neurogastroenterol Motil"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB93|cit93","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1053\/j.gastro.2006.11.002","article-title":"The serotonin signalling system: from basic understanding to drug development for functional GI disorders","volume":"132","author":"Gershon","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB94|cit94","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1023\/A:1020588832411","article-title":"5-HT1-receptor agonist sumatriptan modifies gastric size after 500\u2003ml of water in dyspeptic patients and normal subjects","volume":"47","author":"Malatesta","year":"2002","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB95|cit95","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2982.2008.01260.x","article-title":"A placebo-controlled trial of the 5-HT1A agonist R-137696 on symptoms, visceral hypersensitivity and on impaired accommodation in functional dyspepsia","volume":"21","author":"Tack","year":"2009","journal-title":"Neurogastroenterol Motil"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB96|cit96","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/ajg.2009.223","article-title":"Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis","volume":"104","author":"Ford","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB97|cit97","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1046\/j.1365-2036.1996.30172000.x","article-title":"Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?","volume":"10","author":"Maxton","year":"1996","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB98|cit98","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1001\/archinte.161.14.1733","article-title":"A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome","volume":"161","author":"Camilleri","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB99|cit99","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1111\/j.1572-0241.2004.30509.x","article-title":"Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome","volume":"99","author":"Chey","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB100|cit100","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1572-0241.2005.40365.x","article-title":"A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS","volume":"100","author":"Chang","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB101|cit101","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/j.1572-0241.1999.01440.x","article-title":"Symptom differences in moderate to severe IBS patients based on predominant bowel habit","volume":"94","author":"Schmulson","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB102|cit102","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1542-3565(03)70039-1","article-title":"The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study","volume":"1","author":"Kuiken","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB103|cit103","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1365-2036.2005.02566.x","article-title":"The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study","volume":"22","author":"Vahedi","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB104|cit104","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1572-0241.2004.04127.x","article-title":"Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial","volume":"99","author":"Tabas","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"Suppl. A","key":"10.1111\/j.1365-2036.2011.04637.x-BIB105|cit105","doi-asserted-by":"crossref","first-page":"71A","DOI":"10.1155\/1999\/598659","article-title":"Role of opioid ligands in the irritable bowel syndrome","volume":"13","author":"Corazziari","year":"1999","journal-title":"Can J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB106|cit106","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0163-7258(95)02053-5","article-title":"Insights into opioid action in the intestinal tract","volume":"69","author":"De Luca","year":"1996","journal-title":"Pharmacol Ther"},{"issue":"5 Pt 1","key":"10.1111\/j.1365-2036.2011.04637.x-BIB107|cit107","first-page":"G979","article-title":"5-HT4 receptor agonists and delta-opioid receptor antagonists act synergistically to stimulate colonic propulsion","volume":"275","author":"Foxx-Orenstein","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB108|cit108","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1007\/BF02087560","article-title":"Double-blind dose-response multicenter comparison of fedotozine and placebo in treatment of nonulcer dyspepsia","volume":"39","author":"Fraitag","year":"1994","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB109|cit109","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1007\/BF02209014","article-title":"Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study","volume":"40","author":"Dapoigny","year":"1995","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB110|cit110","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1046\/j.1365-2036.2002.01320.x","article-title":"Naloxone treatment for irritable bowel syndrome - a randomized controlled trial with an oral formulation","volume":"16","author":"Hawkes","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB111|cit111","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0022-3565(25)33584-6","article-title":"Role of alpha-2 adrenergic receptors in the control of diarrhea and intestinal motility","volume":"225","author":"Doherty","year":"1983","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB112|cit112","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2036.1988.tb00728.x","article-title":"Double-blind study of an alpha 2 agonist in the treatment of irritable bowel syndrome","volume":"2","author":"Prior","year":"1988","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB113|cit113","first-page":"191","article-title":"The effect of two antidiarrhoeal drugs on the psychosocial adjustment to illness in chronic functional diarrhoea","volume":"42","author":"Dumitrascu","year":"2004","journal-title":"Rom J Intern Med"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB114|cit114","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1345\/aph.1K345","article-title":"Rifaximin treatment for symptoms of irritable bowel syndrome","volume":"42","author":"Fumi","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB115|cit115","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1046\/j.1365-2036.2000.00808.x","article-title":"Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms","volume":"14","author":"Di Stefano","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB116|cit116","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2006.00458.x","article-title":"A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence","volume":"101","author":"Sharara","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB117|cit117","first-page":"145","article-title":"The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial","volume":"17","author":"Pimentel","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB118|cit118","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1590-8658(00)80021-3","article-title":"Bacterial supplementation in the irritable bowel syndrome. A randomized double-blind placebo-controlled crossover study","volume":"32","author":"O\u2019Sullivan","year":"2000","journal-title":"Dig Liver Dis"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB119|cit119","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(98)02146-1","article-title":"Abnormal colonic fermentation in irritable bowel syndrome","volume":"352","author":"King","year":"1998","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB120|cit120","first-page":"2293","article-title":"Acute fatty liver of pregnancy, hemolysis, elevated liver enzymes, and low platelets syndrome, and long chain 3-hydroxyacyl-coenzyme Adehydrogenase deficiency","volume":"91","author":"Treem","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB121|cit121","volume-title":"Guidelines for the Evaluation of Probiotics in Food","author":"FAO\/WHO","year":"2002"},{"issue":"Suppl. 2","key":"10.1111\/j.1365-2036.2011.04637.x-BIB122|cit122","doi-asserted-by":"crossref","first-page":"361S","DOI":"10.1093\/ajcn\/73.2.361s","article-title":"Probiotics, prebiotics, and synbiotics - approaching a definition","volume":"73","author":"Schrezenmeir","year":"2001","journal-title":"Am J Clin Nutr"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB123|cit123","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/jn\/125.6.1401","article-title":"Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics","volume":"125","author":"Gibson","year":"1995","journal-title":"J Nutr"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB124|cit124","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/j.1572-0241.2000.02015.x","article-title":"Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome","volume":"95","author":"Nobaek","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB125|cit125","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.clnu.2005.06.001","article-title":"The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome-a double blind, placebo-controlled, randomized study","volume":"24","author":"Niv","year":"2005","journal-title":"Clin Nutr"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB126|cit126","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1007\/s10620-006-9297-8","article-title":"Efficacy of probiotics and nutrients in functional gastrointestinal disorders: a preliminary clinical trial","volume":"51","author":"Kim","year":"2006","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB127|cit127","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3810\/pgm.2009.03.1984","article-title":"Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS","volume":"121","author":"Hun","year":"2009","journal-title":"Postgrad Med"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB128|cit128","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1155\/2003\/654907","article-title":"Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation","volume":"17","author":"Koebnick","year":"2003","journal-title":"Can J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB129|cit129","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-230X-9-85","article-title":"A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-based product on functional intestinal gas symptoms","volume":"9","author":"Kalman","year":"2009","journal-title":"BMC Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB130|cit130","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1572-0241.2006.00734.x","article-title":"Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome","volume":"101","author":"Whorwell","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB131|cit131","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1053\/j.gastro.2004.11.050","article-title":"Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles","volume":"128","author":"O\u2019Mahony","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB132|cit132","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/ajcn\/55.1.78","article-title":"Survival of Bifidobacteria ingested via fermented milk during their passage through the human small intestine: an in vivo study using intestinal perfusion","volume":"55","author":"Pochart","year":"1992","journal-title":"Am J Clin Nutr"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB133|cit133","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2036.2007.03362.x","article-title":"Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind,controlled trial","volume":"26","author":"Guyonnet","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB134|cit134","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1017\/S0007114509990882","article-title":"Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minordigestive symptoms: a randomised, double-blind, parallel, controlled study","volume":"102","author":"Guyonnet","year":"2009","journal-title":"Br J Nutr"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB135|cit135","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2036.2005.02579.x","article-title":"A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention","volume":"22","author":"Kajander","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB136|cit136","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1023\/A:1020501202369","article-title":"Efficacy of probiotic use in acute diarrhea in children: a meta-analysis","volume":"47","author":"Huang","year":"2002","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB137|cit137","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000063075","article-title":"Effect of probiotics on constipation, fecal azoreductase activity and fecal mucin content in the elderly","volume":"46","author":"Ouwehand","year":"2002","journal-title":"Ann Nutr Metab"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB138|cit138","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1046\/j.1365-2036.2003.01543.x","article-title":"A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome","volume":"17","author":"Kim","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB139|cit139","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-2982.2005.00695.x","article-title":"A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating","volume":"17","author":"Kim","year":"2005","journal-title":"Neurogastroenterol Motil"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB140|cit140","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/ajcn\/72.6.1570","article-title":"Efficacy, safety, and tolerability of fructooligosaccharides in the treatment of irritable bowel syndrome","volume":"72","author":"Olesen","year":"2000","journal-title":"Am J Clin Nutr"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB141|cit141","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1365-2036.2008.03911.x","article-title":"Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome","volume":"29","author":"Silk","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB142|cit142","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1443-9573.2004.00176.x","article-title":"Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome","volume":"5","author":"Tsuchiya","year":"2004","journal-title":"Chin J Dig Dis"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB143|cit143","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s10620-006-9079-3","article-title":"The efficacy of an herbal medicine, Carmint, on the relief of abdominal pain and bloating in patients with irritable bowel syndrome: a pilot study","volume":"51","author":"Vejdani","year":"2006","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB144|cit144","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ajg.2009.577","article-title":"A randomized, double-blind, placebo-controlled trial of St John\u2019s Word for treating irritable bowel syndrome","volume":"105","author":"Saito","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB145|cit145","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000064936","article-title":"A novel treatment for constipation-predominant irritable bowel syndrome using Padma Lax, a Tibetan herbal formula","volume":"65","author":"Sallon","year":"2002","journal-title":"Digestion"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB146|cit146","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/SGA.0b013e3181b2c920","article-title":"Symptom management for irritable bowel syndrome: a pilot randomized controlled trial of acupuncture\/moxibustion","volume":"32","author":"Anastasi","year":"2009","journal-title":"Gastroenterol Nurs"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB147|cit147","doi-asserted-by":"crossref","first-page":"663","DOI":"10.7326\/0003-4819-134-8-200104170-00012","article-title":"The revised CONSORT statement for reporting randomized trials: explanation and elaboration","volume":"134","author":"Altman","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB148|cit148","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/107555302753507212","article-title":"Standards for reporting interventions in controlled trials of acupuncture: the STRICTA recommendations","volume":"8","author":"MacPherson","year":"2002","journal-title":"J Altern Complement Med"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB149|cit149","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1210\/jc.2002-021057","article-title":"Melatonin in patients with reduced REM sleep duration: two randomized controlled trials","volume":"89","author":"Kunz","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl. 2","key":"10.1111\/j.1365-2036.2011.04637.x-BIB150|cit150","first-page":"33","article-title":"Thirty four years since the discovery of gastrointestinal melatonin","volume":"59","author":"Bubenik","year":"2008","journal-title":"J Physiol Pharmacol"},{"issue":"Suppl. 6","key":"10.1111\/j.1365-2036.2011.04637.x-BIB151|cit151","first-page":"97","article-title":"Melatonin and serotonin effects on gastrointestinal motility","volume":"58","author":"Thor","year":"2007","journal-title":"J Physiol Pharmacol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB152|cit152","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1136\/gut.2004.062034","article-title":"Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study","volume":"54","author":"Song","year":"2005","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB153|cit153","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/S0140-6736(84)92793-4","article-title":"Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome","volume":"2","author":"Whorwell","year":"1984","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB154|cit154","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/ajg.2010.58","article-title":"Differences in gastrointestinal symptoms according to gender in Rome II positive IBS and dyspepsia in a Latin American population","volume":"105","author":"Schmulson","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB155|cit155","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1365-2036.2010.04409.x","article-title":"Meta-analysis: do irritable bowel syndrome symptoms vary between men and women?","volume":"32","author":"Adeyemo","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl. 2","key":"10.1111\/j.1365-2036.2011.04637.x-BIB156|cit156","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.genm.2009.03.004","article-title":"Do fluctuations in ovarian hormones affect gastrointestinal symptoms in women with irritable bowel syndrome?","volume":"6","author":"Heitkemper","year":"2009","journal-title":"Gend Med"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB157|cit157","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/BF02093778","article-title":"Effect of leuprolide acetate in patients with moderate to severe functional bowel disease. Double-blind, placebo-controlled study","volume":"39","author":"Mathias","year":"1994","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1365-2036.2011.04637.x-BIB158|cit158","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1023\/A:1018888631286","article-title":"Effect of leuprolide acetate in treatment of abdominal pain and nausea in premenopausal women with functional bowel disease: a double-blind, placebo-controlled, randomized study","volume":"43","author":"Mathias","year":"1998","journal-title":"Dig Dis Sci"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2011.04637.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2036.2011.04637.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T18:45:07Z","timestamp":1741113907000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2011.04637.x"}},"subtitle":["Review: treatment of bloating and distension"],"short-title":[],"issued":{"date-parts":[[2011,3,29]]},"references-count":158,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,5]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2011.04637.x","relation":{},"ISSN":["0269-2813"],"issn-type":[{"value":"0269-2813","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3,29]]}}}